Compare Air Products & Chemicals, Inc. (APD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Air Products & Chemicals, Inc. trades at $301.71 (market cap $66.70B), while Recursion Pharmaceuticals Inc trades at $3.52 (market cap $1.89B). The key difference: Air Products & Chemicals, Inc. is far larger — about 35.3× Recursion Pharmaceuticals Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.42% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| APD | RXRX | |
|---|---|---|
Market Cap | $66.70B | $1.89B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $6.79 |
52-Week Low | $230.42 | $2.84 |
Enterprise Value | $84.11B | $1.31B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APD trades at $299.53, up 1.24% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and strategic project exits, like the Louisiana Clean Energy Complex, have boosted investor confidence. The company maintains solid profitability margins but faces pressure from a negative net income in 2025 due to a pre-tax charge. Cash flow trends show volatility, with significant investing outflows for growth initiatives.
The outlook is positive with a consensus price target of $324.89, implying ~8% upside. Risks include high debt levels, execution on new projects, and macroeconomic sensitivity. Long-term growth is supported by renewable energy investments, but near-term profitability recovery is key for sustained gains.
RXRX trades at $3.56, down 5.32% today, with a bullish technical signal from moving averages but concerning fundamentals. The company shows deep losses with a -851.51% net income margin and negative cash flow from operations, though it has beaten earnings estimates for three consecutive quarters. Analyst consensus is mixed with a $7.83 price target representing significant upside potential from current levels.
While technical indicators suggest near-term strength and analyst targets imply 120% upside, RXRX faces substantial execution risks as a pre-revenue biotech. The company's AI-driven drug discovery platform shows promise but requires successful clinical outcomes to justify its valuation. High cash burn and negative profitability metrics present significant challenges for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
